SynAct Pharma AB (STO:SYNACT)

SynAct Pharma AB Income Statement

Financials in millions SEK. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Selling, General & Admin	40.49	33.93	35.61	16.23	8.81
Research & Development	49.31	105.06	70.07	60.49	22.79
Other Operating Expenses	0.18	-0.04	-0.11	-0.16	-0.31
Operating Expenses	89.98	138.94	105.57	76.56	31.29
Operating Income	-89.98	-138.94	-105.57	-76.56	-31.29
Interest Expense	-0.85	-0.8	-0.29	-0.11	-0.05
Interest & Investment Income	-	0.59	0.05	-	0.03
Currency Exchange Gain (Loss)	-	0.33	-1.25	-0.15	-
Other Non Operating Income (Expenses)	-	-0	0	-	-
EBT Excluding Unusual Items	-90.83	-138.82	-107.07	-76.81	-31.3
Merger & Restructuring Charges	-	-10.9	-	-	-
Impairment of Goodwill	-	-74.56	-	-	-
Pretax Income	-90.83	-224.28	-107.07	-76.81	-31.3
Income Tax Expense	-8.42	-8.47	-7.86	-7.51	-4.75
Net Income	-82.4	-215.81	-99.21	-69.3	-26.55
Net Income to Common	-82.4	-215.81	-99.21	-69.3	-26.55
Shares Outstanding (Basic)	40	33	28	26	22
Shares Outstanding (Diluted)	40	33	28	26	22
Shares Change (YoY)	21.55%	17.90%	6.72%	19.95%	43.06%
EPS (Basic)	-2.08	-6.64	-3.60	-2.68	-1.23
EPS (Diluted)	-2.08	-6.64	-3.60	-2.68	-1.23
Free Cash Flow	-89.2	-100.18	-117.56	-65	-33.24
Free Cash Flow Per Share	-2.26	-3.08	-4.26	-2.51	-1.54
EBITDA	-15.4	-64.36	-	-	-30.9
D&A For EBITDA	74.58	74.58	-	-	0.38
EBIT	-89.98	-138.94	-105.57	-76.56	-31.29

Source: S&P Capital IQ. Standard template. Financial Sources.